Table A1.

<p>List of COPCOV study sites. Table A2. Baseline characteristics in the COPCOV trial (Per Protocol Analysis). Table A3. Outcomes of Chloroquine/Hydroxychloroquine and Placebo Pre-exposure Prophylaxis against COVID-19 in the COPCOV study (Per Protocol Analysis). Table A4. Summary of Serious Adverse Events in the COPCOV study. Table A5. Primary and secondary outcomes of Chloroquine/Hydroxychloroquine Therapy for Pre-exposure Prophylaxis against COVID-19 (missing outcomes treated as not having had COVID-19 during the study period) ITT–Results presented as “Risk differences.” Table A6. Outcomes of Chloroquine/Hydroxychloroquine and Placebo Pre-exposure Prophylaxis against COVID-19 in the COPCOV study (removing cases for which the SEAC judged that a study endpoint could not be determined). Table A7. Summary characteristics of previously published pre-exposure prophylaxis studies considered for meta-analysis. Table A8. Listing of causes of PCR-confirmed respiratory illness. Fig A1. Atlas showing those countries in which investigators were contacted to enquire whether they would be interested in, and able to join the COPCOV study. Fig A2. Atlas showing the location of the COPCOV trial sites which recruited participants, the 4-aminoquinoline tested, and the approximate numbers recruited. Fig A3. Graph showing cumulative enrollment over time (per week) by country. Fig A4. Funnel plot showing the 4-aminoquinoline COVID-19 pre-exposure chemoprevention RCTs included in the prespecified meta-analysis, and the relationship between point estimate risk ratios for the primary outcome and the corresponding standard errors. Fig A5. Meta-analysis of 4-aminoquinoline COVID-19 pre-exposure chemoprevention RCTs based on individual study primary endpoints using Risk Of Bias tool (RoB 2). Fig A6. Meta-analysis of the safety and tolerability outcomes in COVID-19 chemoprevention RCTs using the same methodology as reported in the WHO living guideline [<a href="http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1004428#pmed.1004428.ref024" target="_blank">24</a>]. Fig A7. Meta-analysis of adverse events leading to treatment discontinuation reported in double-blind, placebo-controlled, 4-aminoquinoline COVID-19 pre-exposure chemoprevention RCTs. Fig A8. Graph showing cumulative loss to follow-up (LTFU) for Hydroxychloroquine/ Chloroquine arms and Placebo arm.</p> <p>(DOCX)</p>